Arsenicals in hematologic cancers

Seminars in Oncology

Volumn 27, Issue 5, 2000, Pages 495-501

  Novick, S C ^a   Warrell R P , Jr ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; ORGANOARSENIC DERIVATIVE;

ACUTE MYELOBLASTIC LEUKEMIA; BLOOD DISEASE; CANCER REGRESSION; CLINICAL TRIAL; CONFERENCE PAPER; DOSE CALCULATION; DRUG EFFICACY; DRUG MECHANISM; FATIGUE; FLUID RETENTION; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; LEUKOCYTOSIS; LONG QT SYNDROME; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PERMISSIBLE DOSE; MULTICENTER STUDY; MULTIPLE MYELOMA; MUSCULOSKELETAL DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; RETINOIC ACID SYNDROME; SKIN MANIFESTATION; SOLID TUMOR; VERTIGO; WEIGHT GAIN;

ANIMAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; HEMATOLOGIC NEOPLASMS; HUMAN; LEUKEMIA, PROMYELOCYTIC, ACUTE; OXIDES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0033792785     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (57)

1. Heavy metals and heavy metal antagonists
2. Arsenic as a therapeutic agent in chronic myeloid leukemia
3. Chronic arsenical poisoning during the treatment of chronic myeloid leukaemia
4. Medicinal arsenic and internal malignancies
5. Arsenic and cancer
6. Chemotherapy studies in an animal tumor spectrum: II. Sensitivity of tumors to fourteen antitumor chemicals
7. The use of selected sulfhydryl inhibitors in a preferential drug attack on cancer
8. In vitro test of anticancer activity of Ailing-1
9. Treatment of acute promyelocytic leukemia by Ailing-1 therapy with use of syndrome differentiation of traditional Chinese medicine
10. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia
11. Use of arsenic trioxide (As203) in the treatment of APL: I. Remission induction in relapsed patients and pharmacokinetics
12. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in patients at relapse
13. 3) in the treatment of acute promyelocytic leukemia: As203 induces NB4 cell apoptosis with down regulation of Bcl-2 expression and modulation of PML-RARa/Pml proteins
14. Studies on treatment of acute promyelocytic lymphoma with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients
15. 3) in acute promyelocytic leukemia
16. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
17. US multicenter trial of arsenic trioxide in acute promyelocytic leukemia (APL)
18. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukemia
19. 3) in patients with solid tumors
20. Dose-ranging and clinical pharmacologic study of arsenic trioxide in patients with advanced hematologic cancers
21. Traditional Chinese and Western medicine in the treatment of 27 patients with malignant lymphoma
22. Marked antitumor effect of arsenic trioxide (As2O3) in high risk refractory multiple myeloma
23. Response and toxicity associated with dose escalation of arsenic trioxide in the treatment of resistant acute promyelocytic leukemia
24. Leukocytosis and the 'retinoic acid syndrome' during induction treatment of acute promyelocytic leukemia with arsenic trioxide
25. The 'retinoic acid syndrome' in acute promyelocytic leukemia
26. Retinoic acid syndrome
27. A 'retinoic acid syndrome' observed in two cases of acute promyelocytic leukemia
28. Toxicology of environmental arsenic
29. Arsenic - State of the art
30. Arsenic and respiratory cancer in man: An occupational study
31. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3)
32. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells
33. The PML and PML/RARα domains: From autoimmunity to molecular oncology and from retinoic acid to arsenic
34. Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia
35. Targeted disruption of the PML gene of acute promyelocytic leukemia
36. Growth and tumor suppressive properties of the PML gene of acute promyelocytic leukemia in PML-/- mice
37. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML/RARα independent manner
38. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients
39. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells
40. Induction of apoptosis by ASK 1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways
41. Stress signals for apoptosis: Ceramide and c-jun kinase
42. Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway
43. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide though modulation of the glutathione redox system
44. Organic arsenical melarsoprol shows growth suppressive activity via programmed cell death on myeloid and lymphoid leukemia derived cell lines
45. Arsenic trioxide induces apoptosis in K562 chronic myelogenous leukemia (CML) cells
46. 3) in PML-RARα and PLZF-RARα transgenic mice as models of APL
47. 3) in cell lines derived from chronic B cell lymphoproliferative disorders
48. Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: Activation of caspases and down-regulation of BCL-2 protein
49. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms
50. Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines
51. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations
52. Arsenic trioxide inhibits cell survival in a variety of cancer cell types
53. Cytotoxicity of arsenic trioxide in cancer cell lines
54. 3) activity spectrum in human tumors
55. Arsenic trioxide is an equipotent inducer of apoptosis in androgen-dependent and androgen-independent LNCaP prostate cancer cell sublines
56. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia